Literature DB >> 21482747

Secretion of glycosylated pro-B-type natriuretic peptide from normal cardiomyocytes.

Jason M Tonne1, Jarryd M Campbell, Alessandro Cataliotti, Seiga Ohmine, Tayaramma Thatava, Toshie Sakuma, Fima Macheret, Brenda K Huntley, John C Burnett, Yasuhiro Ikeda.   

Abstract

BACKGROUND: B-type natriuretic peptide (BNP), a key cardiac hormone in cardiorenal homeostasis, is produced as a 108 amino acid prohormone, proBNP1-108, which is converted to a biologically active peptide BNP1-32 and an inactive N-terminal (NT)-proBNP1-76. The widely accepted model is that the normal heart releases a proteolytically processed BNP1-32 and NT-proBNP, whereas the diseased heart secretes high amounts of unprocessed/glycosylated proBNP1-108 or inappropriately processed BNPs. In contrast, circulating proBNP1-108 has recently been identified in healthy individuals, indicating that the normal heart also secretes unprocessed proBNP1-108. However, the mechanism of proBNP1-108 secretion from the normal heart remains elusive. Our goal was to determine the molecular mechanisms underlying proBNP1-108 intracellular trafficking and secretion from the normal heart.
METHODS: We expressed preproBNP in cardiomyocytes, and determined the subcellular localization and dominant intracellular and extracellular forms of BNP.
RESULTS: Intracellular immunoreactive BNPs were first accumulated in the Golgi apparatus, and then distributed throughout the cytoplasm as secretory vesicles. The predominant intracellular form of BNP was nonglycosylated proBNP1-108, rather than BNP1-32. Glycosylated proBNP1-108, but not nonglycosylated proBNP1-108, was detected as the major extracellular form in the culture supernatants of preproBNP-expressing cell lines and primary human cardiomyocytes. Ablation of O-glycosylation of proBNP1-108 at T71 residue, near the convertase recognition site, reduced the extracellular proBNP1-108 and increased extracellular BNP1-32.
CONCLUSIONS: Intracellular proBNP trafficking occurs through a conventional Golgi-endoplasmic reticulum pathway. Glycosylation of proBNP1-108 controls the stability and processing of extracellular proBNP1-108. Our data establish a new BNP secretion model in which the normal cardiac cells secrete glycosylated proBNP1-108.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21482747      PMCID: PMC3634583          DOI: 10.1373/clinchem.2010.157438

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  28 in total

1.  Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation.

Authors:  Kentaro Kato; Charlotte Jeanneau; Mads Agervig Tarp; Anna Benet-Pagès; Bettina Lorenz-Depiereux; Eric Paul Bennett; Ulla Mandel; Tim M Strom; Henrik Clausen
Journal:  J Biol Chem       Date:  2006-04-25       Impact factor: 5.157

2.  Stretch-induced hypertrophic growth of cardiocytes and processing of brain-type natriuretic peptide are controlled by proprotein-processing endoprotease furin.

Authors:  Y Sawada; M Suda; H Yokoyama; T Kanda; T Sakamaki; S Tanaka; R Nagai; S Abe; T Takeuchi
Journal:  J Biol Chem       Date:  1997-08-15       Impact factor: 5.157

3.  The precursor to B-type natriuretic peptide is an O-linked glycoprotein.

Authors:  Ute Schellenberger; Jessica O'Rear; Andrew Guzzetta; Rodney A Jue; Andrew A Protter; N Stephen Pollitt
Journal:  Arch Biochem Biophys       Date:  2006-04-19       Impact factor: 4.013

4.  Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure.

Authors:  Adam M Hawkridge; Denise M Heublein; H Robert Bergen; Alessandro Cataliotti; John C Burnett; David C Muddiman
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-17       Impact factor: 11.205

5.  HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte.

Authors:  W C Claycomb; N A Lanson; B S Stallworth; D B Egeland; J B Delcarpio; A Bahinski; N J Izzo
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-17       Impact factor: 11.205

6.  Effect of endogenous natriuretic peptide system on ventricular and coronary function in failing heart.

Authors:  K Yamamoto; J C Burnett; M M Redfield
Journal:  Am J Physiol       Date:  1997-11

7.  Assay for measurement of intact B-type natriuretic peptide prohormone in blood.

Authors:  Isabelle Giuliani; François Rieunier; Catherine Larue; Jean-François Delagneau; Claude Granier; Bernard Pau; Marc Ferrière; Max Saussine; Jean-Paul Cristol; Anne-Marie Dupuy; Emmanuel Merigeon; Delphine Merle; Sylvie Villard
Journal:  Clin Chem       Date:  2006-03-30       Impact factor: 8.327

8.  Molecular cloning of the complementary DNA and gene that encode mouse brain natriuretic peptide and generation of transgenic mice that overexpress the brain natriuretic peptide gene.

Authors:  Y Ogawa; H Itoh; N Tamura; S Suga; T Yoshimasa; M Uehira; S Matsuda; S Shiono; H Nishimoto; K Nakao
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

9.  Structure, expression, and genomic mapping of the mouse natriuretic peptide type-B gene.

Authors:  M E Steinhelper
Journal:  Circ Res       Date:  1993-05       Impact factor: 17.367

10.  Evidence for functional heterogeneity of circulating B-type natriuretic peptide.

Authors:  Faquan Liang; Jessica O'Rear; Ute Schellenberger; Lungkuo Tai; Michael Lasecki; George F Schreiner; Fred S Apple; Alan S Maisel; N Stephen Pollitt; Andrew A Protter
Journal:  J Am Coll Cardiol       Date:  2007-02-26       Impact factor: 24.094

View more
  23 in total

Review 1.  Natriuretic peptides in cardiovascular diseases: current use and perspectives.

Authors:  Massimo Volpe; Speranza Rubattu; John Burnett
Journal:  Eur Heart J       Date:  2013-11-13       Impact factor: 29.983

Review 2.  Rationale and therapeutic opportunities for natriuretic peptide system augmentation in heart failure.

Authors:  Paul M McKie; John C Burnett
Journal:  Curr Heart Fail Rep       Date:  2015-02

Review 3.  BNP molecular forms and processing by the cardiac serine protease corin.

Authors:  Tomoko Ichiki; Brenda K Huntley; John C Burnett
Journal:  Adv Clin Chem       Date:  2013       Impact factor: 5.394

4.  Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP.

Authors:  Fima Macheret; Denise Heublein; Lisa C Costello-Boerrigter; Guido Boerrigter; Paul McKie; Diego Bellavia; Sarah Mangiafico; Yasuhiro Ikeda; Kent Bailey; Christopher G Scott; Sharon Sandberg; Horng H Chen; Lorenzo Malatino; Margaret M Redfield; Richard Rodeheffer; John Burnett; Alessandro Cataliotti
Journal:  J Am Coll Cardiol       Date:  2012-10-16       Impact factor: 24.094

5.  Discovery of O-glycans on atrial natriuretic peptide (ANP) that affect both its proteolytic degradation and potency at its cognate receptor.

Authors:  Lasse H Hansen; Thomas Daugbjerg Madsen; Christoffer K Goth; Henrik Clausen; Yang Chen; Nina Dzhoyashvili; Seethalakshmi R Iyer; S Jeson Sangaralingham; John C Burnett; Jens F Rehfeld; Sergey Y Vakhrushev; Katrine T Schjoldager; Jens P Goetze
Journal:  J Biol Chem       Date:  2019-06-11       Impact factor: 5.157

6.  Corin overexpression improves cardiac function, heart failure, and survival in mice with dilated cardiomyopathy.

Authors:  Inna P Gladysheva; Dong Wang; Rachel A McNamee; Aiilyan K Houng; Almois A Mohamad; T Michael Fan; Guy L Reed
Journal:  Hypertension       Date:  2012-12-10       Impact factor: 10.190

7.  The heart regulates the endocrine response to heart failure: cardiac contribution to circulating neprilysin.

Authors:  Mattia Arrigo; Nicolas Vodovar; Hélène Nougué; Malha Sadoune; Chris J Pemberton; Pamela Ballan; Pierre-Olivier Ludes; Nicolas Gendron; Alain Carpentier; Bernard Cholley; Philippe Bizouarn; Alain Cohen-Solal; Jagmeet P Singh; Jackie Szymonifka; Christian Latremouille; Jane-Lise Samuel; Jean-Marie Launay; Julien Pottecher; A Mark Richards; Quynh A Truong; David M Smadja; Alexandre Mebazaa
Journal:  Eur Heart J       Date:  2018-05-21       Impact factor: 29.983

Review 8.  Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics.

Authors:  Sarah Mangiafico; Lisa C Costello-Boerrigter; Ingrid A Andersen; Alessandro Cataliotti; John C Burnett
Journal:  Eur Heart J       Date:  2012-08-31       Impact factor: 29.983

9.  Proinflammatory Cytokine Interleukin 1β Disrupts β-cell Circadian Clock Function and Regulation of Insulin Secretion.

Authors:  Naureen Javeed; Matthew R Brown; Kuntol Rakshit; Tracy Her; Satish K Sen; Aleksey V Matveyenko
Journal:  Endocrinology       Date:  2021-01-01       Impact factor: 4.736

10.  B-type natriuretic peptide versus amino terminal pro-B type natriuretic peptide: selecting the optimal heart failure marker in patients with impaired kidney function.

Authors:  Lena Jafri; Waqar Kashif; Javed Tai; Imran Siddiqui; Iqbal Azam; Hira Shahzad; Farooq Ghani
Journal:  BMC Nephrol       Date:  2013-05-31       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.